SEARCH · PubMed Health

Results for “PLASMAPHERESIS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources

PubMed1988

[Hemodynamics in donor plasmapheresis].

Several studies have demonstrated that preoperative withdrawal and storage of autologous plasma as fresh frozen plasma is effective in blood conservation. For that purpose patients with elective surgery (orthopaedic surgery, open heart surgery, neurosurgery and others) have to undergo donor plasmapheresis without staying in the hospital. Depending upon the need the procedure can be performed several times preoperatively, taking about 900 ml in a normal weighting subject at once. The collection of autologous plasma should be finished at least 14 days before surgery. In order to investigate the haemodynamic effects of donor plasmapheresis 30 patients scheduled for coronary bypass surgery were devided into two groups. 15 patients underwent plasmapheresis (10 ml plasma/kgbw) by one-needle-technique using a Haemonetics seperator (PCS) after premedication but before onset of anaesthesia. Blood withdrawal was performed with 0.5 ml/kgbw x min. Another 15 patients, serving as control had no plasma withdrawal and were measured at identical times as the other group. Both groups had an identical fluid replacement with 500 ml Ringer's solution during the investigation period. Plasma withdrawn was not substituted by colloidal solution (simulating the situation when plasmapheresis is performed at the outpatient). Haemodynamic measurements (both groups) included heart rate, arterial blood pressure, right- and left-atrial pressure, systemic- and pulmonary-vascular resistance and cardiac output. There were no relevant effects of plasmapheresis on haemodynamic function during and after the investigation period in that patients: neither heart rate, blood pressure or vascular resistance changed significantly nor did pre- and afterload or cardiac index. No differences to the group without plasmapheresis could be observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Transfusion, Autologous↗

PubMed1988

A closer look at plasmapheresis in multiple sclerosis: the cons.

Plasmapheresis has been associated with clinical benefit in autoimmune disorders such as Guillain-Barré syndrome and myasthenia gravis, and this has generated interest in its use in patients with multiple sclerosis (MS). However, clinical trials of plasmapheresis in MS have shown little or no benefit from this intervention. The rationale for using plasmapheresis is the removal of an autoimmune antibody from the circulation. However, this approach relies on the assumption that a pathologic autoantibody is present in the vascular compartment and is in transit to the CNS to sites of MS plaques. In addition, for plasmapheresis to be an expedient therapy, it is essential that the target organ recover its biologic function rapidly following removal of circulating autoantibody. Our own study results and the findings of others have indicated that the cost-benefit ratio of plasmapheresis does not favor its use in patients with MS, alone or in combination with other immunosuppressive therapy. Very little sustained clinical benefit attributable to plasmapheresis has been observed.

Clinical Trials as Topic↗

PubMed1985

Islet cell antibodies in insulin-dependent (type 1) diabetic children treated with plasmapheresis.

Plasma levels of islet cell cytoplasmic and cytotoxic antibodies were determined in 10 children with insulin-dependent diabetes mellitus (IDDM) treated with plasmapheresis shortly after diagnosis, and in 9 children with IDDM treated by conventional means alone. Islet cell cytoplasmic antibody (ICA) titers were determined by indirect immunofluorescence using unfixed sections of human pancreas, and islet cell cytotoxic antibody levels were determined in a complement-dependent antibody-mediated cytotoxicity (C'AMC) assay using a human fetal cloned insulin-producing cell line (JHPI-1) as target. Before plasmapheresis, ICA was present in 7 out of 10 children and C'AMC was positive in 4. Four successive treatments with plasmapheresis did not consistently decrease plasma levels of ICA or C'AMC. ICA was present in 15 out of the total 19 children at diagnosis, and titers of ICA decreased in 12 out of 15 subjects by at least 1 degree of dilution (1:3) at 18-30 months follow-up, whether or not they had been treated with plasmapheresis; C'AMC was positive in 6 out of the 18 children at diagnosis and decreased in 2 out of 6. Plasma levels of C-peptide did not differ at diagnosis but remained higher in the plasmapheresis treated diabetic children at 3 and 18-30 months follow-up. Neither ICA titers nor C'AMC levels correlated with plasma C-peptide responses at 18-30 months. It is concluded that plasmapheresis decreases ICA and C'AMC but is followed rapidly by a rebound effect, and does not affect the rates at which these islet cell antibodies decrease with increasing duration of IDDM.

Adolescent↗

PubMed1984

[Plasmapheresis in the patients with malignant tumor].

Therapeutic plasmapheresis for malignant tumor was first applied scientifically to transmissible tumors in dogs in 1908 by Crile et al. In the 1970s, immunosuppressive factors in the plasma of cancer-bearing patients were described. Plasmapheresis has been widely applied to many human malignant diseases for immunosuppressive factors being removed with new plasma separating methods, sachas continuous centrifugation or membrane plasma separation. Recently more selective removal method have been developed. The effects of plasmapheresis are recognized not only from an immunological point of view but also in performance status. The latter effect perhaps depends on the replacement of fresh frozen plasma rather than the removal mechanism itself. It is thought that plasmapheresis improves not only immunological status, but also homeostasis in patients with malignancies. There are no cancer treatments which improve the performance status of advanced cancer patients except plasmapheresis. In the future, plasmapheresis is likely to receive more attention and further development as an anti-cancer therapy for immunomodulation and fundamental treatment in combined immuno-chemotherapy.

Animals↗

PubMed1983

[Polyneuropathy associated with plasma cell dyscrasia and endocrinological abnormalities--a trial of plasmapheresis].

Plasmapheresis and irradiation of the tumor were performed in conjunction with prednisolone therapy to a severe case of polyneuropathy associated with a solitary sclerotic secreting myeloma and endocrinological abnormalities. The patient was 27-year-old male with progressive history of polyneuropathy of seven months duration. On admission, he was quadriplegic with cranial nerve involvements. Pitting type of generalized edema, skin pigmentation and sensory impairment were also present. Respiratory failure occurred soon after the admission. Plasmapheresis lowered the level of M protein but failed to improve clinical course in the short term. On the other hand, prompt amelioration of clinical symptoms followed the irradiation of the tumor. It is difficult to prove clinical effects of plasmapheresis upon symptoms of chronic polyneuropathy. It is suggested that some humoral factor of myeloma might attribute to this syndrome and secreted at higher rate than our plasmapheresis but easily suppressed by the irradiation of the tumor. We suppose that radiation therapy could be the treatment of the first choice for such a severe case like ours. However, further experiences of plasmapheresis of this syndrome are necessary to determine the effect of plasmapheresis. Some other etiological aspects are also discussed.

Adult↗

PubMed1994

[Plasmapheresis in clinical practice].

Plasmapheresis is an immunomodulatory procedure with immunosuppressive effect. Plasmapheresis involves taking blood, separating off the plasma and returning the red cell-enriched fraction to the patient. In plasmapheresis improvement is due to the removal of mediators of tissue damage. Therapeutic plasmapheresis has been used in many diseases in which immunological mechanisms are proved. It has been noted that there may be a "rebound" in the level of antibodies and immune complexes after plasmapheresis, perhaps due to elimination of feedback suppressor mechanisms. For that reason, plasmapheresis is only effective when used as part of an immunosuppressive regimen which also includes steroids and/or cytotoxic agents.

Humans↗

PubMed1993

[Comparative analysis of various plasmapheresis methods--modern procedures of mechanical plasma collection compared with each other and with manual bag centrifugation procedures].

Four plasmapheresis procedures (manual blood bag centrifugation plasmapheresis, and the three plasmapheresis machines P.C.S./Haemonetics, Autopheresis-C/Baxter-Travenol, Plasmapur Monitor/Organon Teknika) were studied comparatively. The three machine procedures could be performed more easily and more rapidly and were well accepted by donors, autologous donors (patients) and staff. Compared with the traditional, well established manual procedure, a possible impairment of the plasma donors seems reduced rather than raised. Activation of the hemostatic system of the donors, measured with very sensitive methods, was found to be less pronounced when plasmapheresis was performed with the machines than when it was performed conventionally. The plasma product obtained by machine plasmapheresis was found to be of higher quality. All three systems showed less activation of the clotting system. Especially the plasma obtained by the P.C.S. showed a higher clotting factor yield. Plasma obtained by the Autopheresis-C and by the Plasmapur Monitor (both systems are equipped with filters) was markedly less contaminated with cells. The recently found low activation of the clotting system of plasma recipients, however, showed no differences when plasma obtained conventionally or by the Plasmapur Monitor was used. In summary, the new machine plasmapheresis devices offer a good alternative to the conventional blood bag centrifugation method and set new standards for the production of high quality plasma.

Blood Coagulation Tests↗

PubMed1996

Management of plasmapheresis in Germany.

In Germany, plasmapheresis is carried out for many years in a "mixed" system by private and non-profit organisation. Most of the institutions and blood transfusion service, active in the field of plasmapheresis are members of the "Association for the Establishment, Co-ordination and Working Methods of the Plasmapheresis Centres". All centres are authorized by governmental bodies for manufacturing of pharmaceutical products with regulatory controls regarding licensing and accreditation of blood collection establishment. All parties concerned agree that self-sufficiency of plasma has to be achieved. For this purpose there is a shortage of about 400,000 1 of plasma. In 1994, about 240,000 1 of plasma were collected by plasmapheresis, 91% for fractionation and 8.7% for direct clinical uses. In addition about 970,000 1 of plasma were derived from whole blood donations. The dualism of non-profit making and commercial organisations should be regarded as a chance for diversification in the collection and processing of plasma. A long term increase in plasmapheresis plasma can be achieved by initiating plasmapheresis programmes and co-operation using the existing infrastructures and supports the aim for self-sufficiency.

Germany↗

PubMedDate not supplied

The role of commercial plasmapheresis banks on the AIDS epidemic in Mexico.

OBJECTIVE: To characterize the circumstances underlying the epidemic of AIDS associated with blood transfusion in Mexico and to explore the possible mechanisms for its dissemination. METHODS: A retrospective analysis comparing the total number of AIDS cases and transfusion-associated AIDS cases and the male:female ratio reported in Mexico and the U.S. from 1981 to 1996 was done. We analyzed the relationship between the location of plasmapheresis banks and the geographic distribution of transfusion-associated AIDS cases and AIDS cases among paid donors in order to assess the possible role of plasmapheresis banks in its dissemination. RESULTS: The proportion of transfusion-associated AIDS in the total number of cases was significantly higher in Mexico than in the U.S. from 1987 through 1996 (p < .0001). A rapid drop in the male:female ratio of AIDS was observed in Mexico but not in the U.S. coinciding with a growing number of transfusion associated cases; transfusion has been the main risk factor for AIDS in women in our country. In 1986, seven States and Mexico City had plasmapheresis banks: they reported 90% of the cases associated to paid donation and 75% of those associated to transfusion, despite the fact that commercial blood banks without plasmapheresis facilities existed in 23 of the other 24 States. CONCLUSION: There was a difference on the frequency of transfusion associated AIDS between Mexico and the U.S. which reached epidemic proportions in Mexico. We believe that plasmapheresis banks played a major role in the dissemination of the infection in Mexico as paid donors provided a third of the blood used in Mexico in 1986. These findings highlight important implications for the prevention of AIDS in developing countries where commercial plasmapheresis practices are still in operation.

Acquired Immunodeficiency Syndrome↗

PubMed1996

Plasmapheresis in primary dysfunction of hepatic transplants.

BACKGROUND: Primary dysfunction is a failure of graft function which occurs in approximately 5% of transplanted livers. Retransplantation is often required. The presence of elevated serum cytokines interleukin 6 and tumor necrosis factor with hepatic graft dysfunction, as well as the historical benefit of plasmapheresis in fulminant hepatic failure-associated coma suggest a possible role for plasmapheresis therapy in the management of primary graft dysfunction in liver transplantation. DESIGN AND METHODS: We evaluated the effectiveness of plasmapheresis in the management of primary graft dysfunction in 18 patients who underwent orthotopic liver transplantation in this institution. Patients who were diagnosed with primary dysfunction of hepatic grafts underwent a course of four daily plasma exchange procedures. The clinical outcome, patient and graft survival, was compared to that of historical controls. RESULTS: Graft survival at 10 days was 77.7% and 76.2% and patient survival at 100 days was 83.3% and 85.7% in the plasmapheresed and control groups, respectively. The patients who underwent plasmapheresis had a higher incidence of dialysis intervention, 38% versus 19%, indicating more severe graft dysfunction. In the small number of patients compared for concomitant dialysis therapy, patient survival in the plasmapheresed group was 85.7% versus 50% (control), and graft survival was 57.0% versus 50%. Serum cytokine levels of tumor necrosis factor and interleukin 6 were reduced by 66.0% and 55.2%, respectively, with a single procedure. CONCLUSION: Plasmapheresis did not significantly effect graft survival in patients with primary graft dysfunction. An increase in patient survival in severe graft dysfunction with renal failure was noted but was not significant. Removal of elevated serum cytokines TNF and IL-6 was documented.

Adult↗

PubMed1981

Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA.

The effect of plasmapheresis in 8 patients with systemic lupus erythematosus (SLE) was investigated. Drug treatment was maintained at a constant level for at least 4 weeks before plasmapheresis. Levels of immune complexes were measured by a Raji cell radioimmunoassay, and by a solid-phase C1q-binding assay. Antibodies to ds-DNA and ss-DNA were measured by the Farr assay. In all cases, immune complexes and antibodies were lowered by plasmapheresis. In 5 patients, plasmapheresis was followed by a rapid rebound of complexes and antibody to pretreatment levels. In 3 in whom plasmapheresis was followed by treatment with cyclophosphamide for 1 month, a sustained immunochemical and clinical improvement followed, lasting in 2 cases for up to 3 years.

Adolescent↗

PubMed1997

Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years.

The catastrophic antiphospholipid syndrome (CAPS) is rare and usually fatal. In this report, we describe an unusual patient who, 31 years after experiencing an atypical preeclampsia-eclampsia presentation known today as the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets), developed CAPS, which seemed to complicate a diagnosis of primary antiphospholipid syndrome. She responded to repeated plasmapheresis over 3 years. Anticoagulants, corticosteroids, intravenous gamma globulin, and intravenous cyclophosphamide had all failed to halt the progression of CAPS, but repeated plasmapheresis not only halted the condition, but it led to the reversal of a leukoencephalopathy. The relationship between HELLP syndrome and CAPS is discussed, and possible pathogenetic mechanisms that explain the efficacy of repeated plasmapheresis in this setting are suggested. It is postulated that perhaps plasmapheresis, through removal of cytokines or other mediators, disrupts the interaction between phospholipid-protein complexes and endothelial cells. Repeated plasmapheresis should be considered in the most refractory cases of CAPS when more conventional treatment regimens have failed.

Aged↗

PubMed2003

Plasmapheresis for severe lipemia: comparison of serum-lipid clearance rates for the plasma-exchange and double-filtration variants.

Patients with extremely high triglyceride levels and associated lipemia are at high risk for acute pancreatitis. To evaluate plasmapheresis efficacy for severe hypertriglyceridemia, 18 patients who had not responded to previous therapies were selected for either the plasma-exchange (PE) or double-filtration (DF) treatment variants. After treatment, the mean serum concentrations for triglyceride and cholesterol fell significantly from 1,977.1 and 436.7 mg/dl to 692.6 and 222 mg/dl, respectively. The cholesterol-removal rate was significantly higher for the PE group (P = 0.0082), which also had a lower incidence of hemolysis during the plasmapheresis treatment (P = 0.0430). Improved clearance of serum triglyceride was strongly associated with a lower level of maximal transmembrane pressure (TMP; P = 0.0030), reduced plasmapheresis duration (P = 0.0035), and higher rates of plasma (P = 0.0255) and blood flow (P = 0.0480) during plasmapheresis. In comparison to reports in the literature, the removal rates for serum lipids were lower in our study, possibly as a consequence of early saturation of the plasma separator resulting from blockage caused by the extremely high level of triglyceride-containing lipoproteins. Therefore, PE may be more suitable for the initial treatment of severe hypertriglyceridemia as saturation is prevented. Increasing blood and plasma flow rates, reduction of the TMP level, and reducing effective plasmapheresis duration will improve the clearance of serum lipids during treatment.

Adult↗

PubMed2006

Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin.

We report the case of 64-year-old female patient with pulmonary embolism and bilateral femoropopliteal deep vein thrombosis caused by heparin-induced thrombocytopenia type II (HIT II) resistant to danaparoid sodium and subsequently administered lepirudin in whom a single late plasmapheresis performed on day 6 of the initiation of treatment of HIT reversed the course of the disease, preventing its highly potential fatal outcome. Primarily administered lepirudin was not only ineffective but even led to further aggravation of the patient's clinical state and platelet count drop in the first stage of the HIT treatment. The improvement of the patient's clinical state was not achieved before therapeutic plasma exchange (TPE) had removed the greatest part of pathogenetic circulating substrate. Only after TPE, lepirudin, introduced again, led to the platelet count recovery. In the subsequent course of the treatment, lepirudin was combined with an overlapping oral anticoagulant. Previously positive heparin aggregation test and fast particle gel heparin-platelet factor 4 immunoassay were normalized as well as the patient's clinical status. Early plasmapheresis, administered within 4 days of the onset of thrombocytopenia in HIT, as a beneficial therapeutic measure in certain individual cases, is indisputable. However, our results do not concur with previously reported findings of the so far most comprehensive study on plasmapheresis performed in the management of HIT with thrombosis, discrediting late plasmapheresis administered 4 days after the onset of the disease not only as ineffective, but even as an aggravating factor. Our results suggest the possible beneficial impact of late plasmapheresis as a method that may reverse a prothrombotic process and lead to a fast improvement in the patient's platelet count, especially in cases initially resistant to thrombin inhibitors.

Arthroplasty, Replacement, Hip↗

PubMed1988

Plasmapheresis in the treatment of acute relapsing inflammatory demyelinating polyradiculoneuropathy associated with human immunodeficiency virus infection: a case report.

Neurologic complications, including both the acute and chronic forms of inflammatory demyelinating polyradiculoneuropathy (IDP) are becoming more prevalent among patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related-complex (ARC). Although the etiology of the above radiculoneuropathies is not known, an autoimmune process has been postulated. Plasmapheresis has been reported to be of benefit in both the acute and chronic forms of these neuropathies. In this report we describe the use of plasmapheresis in the treatment of a patient with ARC and the acute relapsing form of IDP. The treatment consisted of an intensive course of plasmapheresis following his initial presentation and after an acute relapse which occurred several weeks after his initial presentation. Both the initial presentation and relapse involved respiratory compromise necessitating intubation and mechanical ventilation. In both instances marked clinical improvement was achieved after initiation of plasmapheresis. Thus, plasmapheresis may have a role in the management of acute relapsing IDP associated with human immunodeficiency virus infection.

AIDS-Related Complex↗

PubMed1985

Plasmapheresis in paraproteinemia.

Indications, results, techniques, laboratory monitoring and complications of therapeutic plasmapheresis in patients with symptomatic paraproteinemia are reviewed. In paraproteinemia associated with severe complications plasma-pheresis has been used successfully as an emergency treatment, as a treatment that reduces temporarily the paraprotein level until reduction of resynthesis is reached by cytotoxic therapy, or as a longterm adjuvant therapy in cases of slowly proliferating plasmacytoma or lymphoma. Plasmapheresis has not been shown to influence the underlying malignant process. Paraprotein-related complications that can be reduced by plasmapheresis are hyperviscosity, hypervolemia, haemorrhagic diathesis, cryoglobulinemic symptoms, rapidly deteriorating renal insufficiency, visual impairment, and neurologic disturbances. Technically, large-pored plasma filters have some advantage as compared to centrifugation techniques. Paraprotein-specific complications of therapeutic plasmapheresis are rare. As an ancillary treatment, therapeutic plasmapheresis has expanded the therapeutic tools in the management of paraproteinemia.

Acute Kidney Injury↗

PubMed1993

Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy.

We have measured eye muscle antibodies, in immunoblotting, in the serum from five patients with severe ophthalmopathy associated with Graves' hyperthyroidism who underwent plasmapheresis, correlating their levels with clinical features of the eye disorder and response to treatment. Blood taken before each plasma exchange was tested in SDS-polyacrylamide gel electrophoresis and Western blotting for antibodies reactive with pig eye muscle membrane (PEMM) antigens and in a 51Cr release assay for antibodies which are cytotoxic to human eye muscle cells in antibody-dependent cell-mediated cytotoxicity (ADCC). Antibodies reactive with a 64 kDa PEMM antigen were detected in three patients who had eye disease of less than six months duration, but not in the two with more chronic disease. Antibodies against a 95 kDa PEMM antigen were detected in one patient in whom anti-64 kDa antibodies were also demonstrated. All five patients showed significant improvement in their eye disease following plasmapheresis exchange and titres of the anti-64 kDa protein antibody decreased in the three patients with detectable levels before treatment. TSH receptor stimulating antibodies were detected in all five patients before treatment, falling during plasmapheresis in four and becoming undetectable in three by the end of treatment. There was no close correlation between levels of TSH receptor antibodies and titres of anti-64 kDa protein antibodies although both tended to fall during and following plasmapheresis. ADCC tests were negative in all five patients before plasmapheresis but, surprisingly, transiently positive in three following treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

PubMed2003

Early use of plasmapheresis for recurrent post-transplant FSGS.

Recurrence of focal segmental glomerulosclerosis (FSGS) in an allograft is a challenging clinical situation because it frequently results in graft loss. We report our experience with early use of plasmapheresis in recurrent FSGS. Of the 18 (33%) children with biopsy-proven FSGS (in their native kidneys) transplanted at our institution, 6 had recurrence (elevated urine protein/creatinine ratios) post transplant and were treated with plasmapheresis. Patients who received treatment within 1 day of the recurrence (4/6) went into remission after 5-13 plasmapheresis treatments, within 5-27 days of starting treatment. Patients who did not respond to plasmapheresis (2/6) were treated 7 and 17 days after onset of proteinuria; 1 of these had acute tubular necrosis and acute rejection leading to graft loss and the other developed acute rejections, ongoing proteinuria, and subsequent graft loss. All 4 patients who went into remission have maintained good graft function, 22-53 months post transplant. In our experience early institution of plasmapheresis for recurrent post-transplant proteinuria in FSGS is effective.

Adolescent↗